X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) had its target price lifted by equities researchers at HC Wainwright from $3.00 to $5.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 352.49% from the company’s […]
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Equities research analysts at Brookline Capital Management increased their FY2026 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now expects that the company will earn $0.32 per share for the year, […]
HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note released on Friday, Benzinga reports. The brokerage currently has a $3.00 price objective on the stock. Separately, B. Riley lowered X4 Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for […]
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) CEO Paula Ragan sold 199,531 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $0.73, for a total transaction of $145,657.63. Following the completion of the transaction, the chief executive officer now owns 876,347 shares […]